Ziying Yi

Ziying Yi

Auto-generated profile, based on publicly available information

Ziying Yi

Chongqing Key Laboratory of Molecular Oncology and Epigenetics, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2020 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
MLMengqi Lu
Mengqi Lu
YWYushen Wu
Yushen Wu
BZBeilei Zeng
Beilei Zeng
JSJiazheng Sun
Jiazheng Sun
YLYunhai Li
Yunhai Li
GRGuosheng Ren
Guosheng Ren

21 October 2020 in PeerJ
Verified
Journal Article
Open access
PDF file
MWMengxue Wang
Mengxue Wang
MDMeng Dai
Meng Dai
YWYu-Shen Wu
Yu-Shen Wu
ZYZiying Yi
Ziying Yi
YLYunhai Li
Yunhai Li
GRGuosheng Ren
Guosheng Ren
Background: Immunoglobulin superfamily member 10 (IGSF10) is a member of the immunoglobulin superfamily that is expressed at high levels in both the gallbladder and ovary. Currently, the role and possible mechanism of IGSF10 in breast cancer remain unclear. Method: By applying real-time quantitative polymerase chain reaction (qRT-PCR) and immunohistochemistry (IHC), the expression of IGSF10 in breast cancer cells and tissues was detected. We collected the clinical information from 700 patients with breast cancer in The Cancer Genome Atlas (TCGA), and analyzed the relationship between IGSF10 expression and the clinicopathological features and survival outcomes of these patients. The potential mechanisms and pathways associated with IGSF10 in breast cancer were explored by performing a gene set enrichment analysis (GSEA). Results: According to TCGA data, qRT-PCR and IHC experiments, levels of the IGSF10 mRNA and protein were significantly decreased in breast cancer tissues. IGSF10 expression was significantly correlated with age, tumor size, and tumor stage. Moreover, shorter overall survival (OS) and relapse-free survival (RFS) correlated with lower IGSF10 expression, according to the survival analysis. The multivariate analysis identified that IGSF10 as an independent prognostic factor for the OS (hazard ratio (HR) = 1.793, 95% confidence interval (CI) [1.141–2.815], P = 0.011) and RFS (HR = 2.298, 95% CI [1.317–4.010], P = 0.003) of patients with breast cancer. Based on the GSEA, IGSF10 was involved in DNA repair, cell cycle, and glycolysis. IGSF10 was also associated with the PI3K/Akt/mTOR and mTORC1 signaling pathways. Conclusions: This study revealed a clear relationship between IGSF10 expression and the tumorigenesis of breast cancer for the first time. Therefore, further studies are needed to understand the mechanism of IGSF10 in breast cancer.

27 November 2024 in Cancer Immunology Research
Verified
Journal Article
Open access
JSJiazheng Sun
Jiazheng Sun
PWPin Wang
Pin Wang
ZYZiying Yi
Ziying Yi
YWYushen Wu
Yushen Wu
WXWei Yu xian
Wei Yu xian
HLHongzhong Li
Hongzhong Li
The limited infiltration of CD8+ T cells in tumors hampers the effectiveness of T cell–based immunotherapy, yet the mechanisms that limit tumor infiltration by CD8+ T cells remain unclear. Through bulk RNA sequencing of human tumors, we identified a strong correlation between WNT7A expression and reduced CD8+ T-cell infiltration. Further investigation demonstrated that inhibiting WNT7A substantially enhanced MHC-I expression on tumor cells. Mechanistically, WNT7A inhibition inactivated the Wnt/β-catenin signaling pathway and thus resulted in reduced physical interaction between β-catenin and p65 in the cytoplasm, which increased the nuclear translocation of p65 and activated the NF-κB pathway, ultimately promoting the transcription of genes encoding MHC-I molecules. We found that our lead compound, 1365-0109, disrupted the protein–protein interaction between WNT7A and its receptor FZD5, resulting in the upregulation of MHC-I expression. In murine tumor models, both genetic and pharmaceutical suppression of WNT7A led to increased MHC-I levels on tumor cells, and consequently enhanced the infiltration and functionality of CD8+ T cells, which bolstered antitumor immunity and improved the effectiveness of immune checkpoint blockade therapy. These findings have elucidated the intrinsic mechanisms of WNT7A-induced immune suppression, suggesting that therapeutic interventions targeting WNT7A hold promise for enhancing the efficacy of immunotherapy.

4 March 2025
Verified
Other
Open access
JSJiazheng Sun
Jiazheng Sun
PWPin Wang
Pin Wang
ZYZiying Yi
Ziying Yi
YWYushen Wu
Yushen Wu
WXWei Yu xian
Wei Yu xian
HLHongzhong Li
Hongzhong Li
Figure S2 Blocking WNT7A leads to an increase in MHC-I expression.

4 March 2025
Verified
Other
Open access
JSJiazheng Sun
Jiazheng Sun
PWPin Wang
Pin Wang
ZYZiying Yi
Ziying Yi
YWYushen Wu
Yushen Wu
WXWei Yu xian
Wei Yu xian
HLHongzhong Li
Hongzhong Li
Figure S4 Inhibition of WNT7A leads to the upregulation of MHC-I via the NF-κB pathway.

4 March 2025
Verified
Other
Open access
JSJiazheng Sun
Jiazheng Sun
PWPin Wang
Pin Wang
ZYZiying Yi
Ziying Yi
YWYushen Wu
Yushen Wu
WXWei Yu xian
Wei Yu xian
HLHongzhong Li
Hongzhong Li
Figure S3 WNT7A blockage inhibits tumor growth and enhances anti-tumor immunity.